PLK1 and neoplasm: Moreover, the pretreatment of tumor cells with 100 nM BI6727 reduced the IC50 of Olaparib by 10-fold to 5.7 μM (Figure 6D), indicating that, similar to previous cancer cell lines, PLK1 inhibition strongly sensitizes patient-derived tumor cells to Olaparib.